Agios Pharmaceuticals (NASDAQ:AGIO) Given New $53.00 Price Target at Scotiabank

Agios Pharmaceuticals (NASDAQ:AGIO - Free Report) had its target price boosted by Scotiabank from $51.00 to $53.00 in a report issued on Friday morning, Benzinga reports. They currently have a sector outperform rating on the biopharmaceutical company's stock.

Several other equities research analysts also recently weighed in on AGIO. Leerink Partnrs downgraded Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 27th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, September 19th. Raymond James reiterated an "outperform" rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Leerink Partners downgraded Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $60.00 to $56.00 in a report on Friday, September 27th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Agios Pharmaceuticals has a consensus rating of "Hold" and a consensus price target of $52.33.

Agios Pharmaceuticals Trading Up 0.5 %

AGIO stock traded up $0.21 during midday trading on Friday, hitting $44.64. 437,321 shares of the company's stock were exchanged, compared to its average volume of 688,550. Agios Pharmaceuticals has a 1-year low of $20.40 and a 1-year high of $53.28. The stock has a market capitalization of $2.54 billion, a PE ratio of -6.78, a P/E/G ratio of 0.47 and a beta of 0.75. The business has a 50-day simple moving average of $44.68 and a two-hundred day simple moving average of $42.01.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The company had revenue of $8.60 million for the quarter, compared to analysts' expectations of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The company's quarterly revenue was up 28.4% compared to the same quarter last year. During the same period last year, the business earned ($1.51) EPS. As a group, research analysts expect that Agios Pharmaceuticals will post 7.54 EPS for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the firm's stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares of the company's stock, valued at approximately $988,346.74. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Brian Goff sold 11,091 shares of the firm's stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the sale, the chief executive officer now owns 78,792 shares in the company, valued at approximately $3,368,358. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares of the company's stock, valued at $988,346.74. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.93% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Farallon Capital Management LLC boosted its stake in Agios Pharmaceuticals by 34.1% in the 1st quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company's stock worth $163,469,000 after buying an additional 1,423,000 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Agios Pharmaceuticals by 307.8% during the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company's stock worth $48,887,000 after acquiring an additional 855,739 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Agios Pharmaceuticals by 23.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company's stock worth $58,861,000 after acquiring an additional 388,381 shares during the last quarter. Frazier Life Sciences Management L.P. grew its holdings in Agios Pharmaceuticals by 66.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company's stock valued at $37,600,000 after purchasing an additional 348,808 shares during the period. Finally, Candriam S.C.A. acquired a new position in Agios Pharmaceuticals during the second quarter worth approximately $13,922,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.